Our annual conference is next week and we have a fantastic line up of over 70 speakers. This is why a record number of participants are now registered for the 4th annual Neurotech Conference in San Francisco next week. What do you have to gain?
- Find out about new product licensing and partnering opportunities
- Discover emerging technologies and companies
- Learn what venture and strategic investors are looking for
- Hear about cutting edge translational research and funding opportunities
- Meet and network with decision makers from across commercial neuroscience
Register Now - View Agenda with 70 Presenting Neurotech Executives
Join confirmed attendees who are now using the participant directory to network and set up one-on-one meetings: Aberdare Ventures, Accera, Accelemed, Adlyfe, Advanced Brain Monitoring, Alexza Pharmaceuticals, Alfred Mann Foundation, Alpha Omega, Alzheimer's Drug Discovery Foundation, Alzheimer's Research Forum and SWAN, ARCH Venture Partners, Arcion Therapeutics, Athena Technology Ventures, Autonomic Technologies, Avanir Pharmaceuticals, Avineuro Pharmaceuticals, Azevan Pharmaceuticals, Banyan Biomarkers, Bay City Capital, Bayhill Therapeutics, BCC Partners, Betterhumans, BioBehavioral Diagnostics, BioBusiness TV, BioCentury, Biotechnology Value Fund, BiotechPartnering Solutions, Boston Scientific Neuromodulation, Brain Resource, Brain Trust Accelerator Fund, BrainCells Inc., BrainScope Company, Brown Institute for Brain Science, Brown University, CCC Medical Devices, Center for BioEntrepreneurship UCSF, Ceregene, CHDI , Cloudera, Cognitive Drug Research, CollabRx, CoMentis, Conde Nast Portfolio Magazine, Corcept Therapeutics, CorTechs Labs Inc, Cortex Pharmaceuticals, Creative Commons, CureNeuro, Cyberonics, Cypress Bioscience, Cytox Group, D. E. Shaw Ventures, De Novo Ventures, Desitin Arzneimittel GMBH, DLA Piper, Electrical Geodesics, Eli Lilly and Company, Elminda , Elsevier Business Intelligence, Embera NeuroTherapeutics, Eos Neuroscience, Epilepsy Foundation, Epilepsy Therapy Project, EpiNano, Ernst Gallo Research Center, Ewing Marion Kauffman Foundation, Fast Forward, FasterCures, Feinstein Kean Healthcare, Flywheel Ventures, Genentech, Genesys Capital, Genzyme Corporation, George Greenstein Institute, Gladstone Institutes, Great Lakes BioSciences, HLM Venture Partners, Hoffmann-La Roche, Huntington's Disease Society of America, IDSC, LLC, Impax Pharmaceuticals, Inc. Magazine, iNetworks Advisors, Innovative NeuroTechnologies, Intellect Neurosciences, International Neuromodulation Society, Int'l Mental Health Research Organization, J. David Gladstone Institutes, Jan Medical, K&L Gates, Kansas Univ. Med. Center, Kappametrics Inc., Kinetics Foundation, Larta, Liverpool University, Lockheed Martin Aculight, Lou Ruvo Brain Institute, MDA Venture Philanthropy, MedAvante, MedStrategy, Medtronic, Medtronic Neuromodulation, Merck & Co, Merck Research Laboratories, Merz Pharmaceuticals GmbH, Methylation Sciences, Michael J. Fox Foundation, MicroTransponder, MIT Media Lab, Myelin Repair Foundation, Nabi Biopharmaceuticals, National Institutes of Health, Neostim, NeuroInsights, Neurologix, Neurolutions, Neuromodulation Ventures, Neuronascent, Neuronetics, Neuronetrix, NeuroNexus Technologies, NeuroNova AB, NeuroPace, Neurotechnology Industry Organization, Neurotech Reports, NeuroVentures, NFocus Neuromedical, NINDS/NIH, NIMH/NIH, North American Neuromodulation Society, Novartis Pharma AG, Novo Ventures, Omneuron, OpusGen, Otonomy, Oxford Bioscience Partners, Parexel, Pfizer, Pharmawire/Financial Times, Philips Research, Prexa Pharmaceuticals, Prize4Life, Prospect Venture Partners, Proteus Biomedical, PsychoGenics, PureTech Ventures, Q Therapeutics, QiG Group, San Jose BioCenter, Sanderling Ventures, Sandia National Laboratories, Satoris, Scale Venture Partners, Science Magazine, Science Futures, Siemens Venture Capital, Sierra Neuropharmaceuticals, Signum Biosciences, Silere Medical Technology, Shire, Sound Pharmaceuticals, SpectrumCare, Spinal Modulation, Spinal Muscular Atrophy Foundation, Stanford University, StemCells, Supernus Pharmaceuticals, Synsonix, Targacept, Technology Partners, Technology Review, Teva Pharmaceutical Industries, Texcel Medical, Thallo Bioscience Advisors, The Gray Sheet, The Jackson Laboratory, The Parkinson's Institute and Clinical Center, Thomas, McNerney & Partners, Transcept Pharmaceuticals, Tronics Medtech, UC Berkeley, Univ of Texas HSC/CCT, Univeristy of Pittsburgh Medical Center, University of California, Irvine, University of Utah, Versant Ventures, Vivo Ventures, Weill Cornell Medical College, World Brain Forum, Xytis Inc., Zarlink Semiconductor, Zoomedia
Reserve Your Spot Now and View Agenda. Don't miss this excellent networking opportunity to discover partnering opportunities from across commercial neuroscience.
Date: May 11-13, 2009
Location: St. Regis, San Francisco
Audience: CEOs, CSOs, CFOs, business development executives, non-profit leaders, corporate investors, venture capitalists, private equity investors, institutional investors, technology transfer experts, licensing executives
May 4, 2009
I took part in a several hour group discussion at the Decade of Mind conference back in January on neurotech and national security. Chris Forsythe of Sandia National Laboratories & James Giordano of Georgetown University & Potomac Institute for Policy Studies wrote up this nice synopsis of the discussion.
"We are approaching a time when brain science will be critical to our national security. Whether the basis for enhanced human performance or more intelligent machines, the impacts will be broad, motivating innovations in technologies, policies and practices. The prospects are similar to an earlier time ( i.e.- the 19th century) when advances in scientific understanding of the chemistry of explosives revolutionized weaponry, and the ways in which war was conducted. Brain science is poised to incur similarly far-reaching changes. There is need for a coordinated strategy as brain science becomes an increasingly important component of, and the basis for potential threats to, our national security. This strategy should provide a roadmap for translating advances, bolstered by initiatives such as the proposed Decade of the Mind and National Neurotechnology Initiative, to the national security domain. This strategy should also assure safeguards and governance, promoting U.S. leadership in establishing standards for the application of brain science to military, intelligence and other security domains. At the Fourth Decade of the Mind Conference, January 13-15, 2009, four areas were identified wherein national security will be impacted by advances in brain science.
1. Adversarial Application of Brain Science exemplified by: (a) nanoparticles engineered to affect specific brain processes, (b) “super soldiers” created through pharmaceuticals and/or brain stimulation enabling troops to think/react more quickly, exert greater concentration, etc. (c) brain imaging for interrogation/lie detection, and (d) intelligent machines replicating the mechanisms by which humans and other animals perform signal detection, information processing, etc.
2. Expanding the Limits of Human-Machine Systems Performance through technologies overcoming human perceptual and cognitive constraints limiting today’s technological solutions.
3. “Learner Specific” Education and Training - customized to the variable strengths and weaknesses of learners minimizing knowledge acquisition time and maximizing outcomes.
4. Brain Injuries and Disorders - treatments curtailing and reversing brain damage with understanding of mechanisms underlying psychological resilience suggesting techniques for assessing susceptibility, protecting against and treating stress-related pathologies.
It is reasonable to assume other nations have focused research and development on each of these areas. We assert that the U.S. should not engage in compensatory, “catch-up” research programs, as this will be costly to our national security from both an economic and pragmatic perspective. There are few fields that are as rapidly advancing as brain science. Combined with innovations in nanotechnology, genetics, microelectronics, etc., advances in brain science will only accelerate, and it is probable that major breakthroughs relevant to national security are both viable and imminently achievable. Consequently, we argue that there is need for a coordinated, strategic effort to address the ramifications of brain science in the interest of our national security."
Note: For more about the legalities of neurowarfare I recommend this paper written by Cornell Law School student Stephen White.
+ TrackBacks (0) | Category: Neurowarfare